Gene Therapy Approved by the FDA

By editor
December 22, 2017

Mid Atlantic Retina is pleased that the FDA has approved gene therapy, voretigene (Luxturna), for very specific uncommon genetic retinal diseases, caused by mutations in the gene RPE65 which may cause a form of Leber Congenital Amaurosis or retinitis pigmentosa.  These disorders cause severe loss of vision starting at birth or in early childhood.  Not...  read more

First Patient Enrolled in PhaseII Study for Dry AMD

By editor
September 9, 2015

Dr Carl Regillo remarks on PhaseII Study for Dry AMD and Mid Atlantic Retina/Wills Eye Hospitals participation in the clinical trials. Click here to read more.